Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $18.4 million.

  • Spyre Therapeutics' Prepaid Assets rose 16862.23% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 16862.23%. This contributed to the annual value of $5.4 million for FY2024, which is 13927.14% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Prepaid Assets is $18.4 million, which was up 16862.23% from $12.3 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Prepaid Assets peaked at $18.4 million during Q3 2025, and registered a low of $2.2 million during Q3 2023.
  • Its 5-year average for Prepaid Assets is $6.2 million, with a median of $5.4 million in 2024.
  • As far as peak fluctuations go, Spyre Therapeutics' Prepaid Assets tumbled by 7222.5% in 2023, and later surged by 23799.44% in 2024.
  • Spyre Therapeutics' Prepaid Assets (Quarter) stood at $4.9 million in 2021, then increased by 24.74% to $6.2 million in 2022, then tumbled by 63.53% to $2.3 million in 2023, then soared by 139.27% to $5.4 million in 2024, then surged by 241.74% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $12.3 million for Q2 2025, and $4.9 million during Q1 2025.